Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← Analysis & Perspectives
AvalereMarch 5, 2026

States Shift Away from Bundled Payments for Cell and Gene Therapies to Capture Rebates

Medicaid programs are increasingly moving away from bundled payment methodologies for cell and gene therapies in order to separately identify these drugs and collect manufacturer rebates under the Medicaid Drug Rebate Program. This shift provides more predictable reimbursement for providers but increases rebate exposure for manufacturers. The piece also explores the expansion of CAR-T administration into community outpatient settings and implications for access and reimbursement across payer types.

Pharmacy · Managed Care · Finance

Read the full analysis at Avalere →

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

Share this

More from Avalere

← Analysis & Perspectives

Get the daily briefing.